Jula Inrig - 01 Jul 2025 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Issuer symbol
TVTX
Transactions as of
01 Jul 2025
Net transactions value
-$11,940
Form type
4
Filing time
02 Jul 2025, 17:28:57 UTC
Previous filing
12 Feb 2025
Next filing
29 Dec 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Inrig Jula CHIEF MEDICAL OFFICER C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO /s/ Elizabeth E. Reed, Attorney-in-Fact 02 Jul 2025 0001902368

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVTX Common Stock Sale $11,940 -815 -0.91% $14.65 88,787 01 Jul 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of additional shares to cover the tax obligation that occurred upon the vesting of performance-based restricted stock units (PSUs) that vested in February 2025.